Carregant...
Fingolimod and changes in hematocrit, hemoglobin and red blood cells of patients with multiple sclerosis
Introduction: Fingolimod is the first oral drug approved by Food and Drug Administration (FDA) of United States for treating patients with relapsing-remitting multiple sclerosis (RRMS). Fingolimod acts by immunomodulation but there are still much remained about its different effects. Objectives: The...
Guardat en:
| Publicat a: | Am J Clin Exp Immunol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
e-Century Publishing Corporation
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6726974/ https://ncbi.nlm.nih.gov/pubmed/31497380 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|